Free Trial
NASDAQ:AMRX

Amneal Pharmaceuticals (AMRX) Stock Price, News & Analysis

Amneal Pharmaceuticals logo
$7.40 +0.10 (+1.30%)
As of 11:04 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Amneal Pharmaceuticals Stock (NASDAQ:AMRX)

Key Stats

Today's Range
$7.29
$7.42
50-Day Range
$6.97
$9.01
52-Week Range
$5.56
$9.48
Volume
146,095 shs
Average Volume
1.41 million shs
Market Capitalization
$2.29 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.80
Consensus Rating
Buy

Company Overview

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Amneal Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

AMRX MarketRank™: 

Amneal Pharmaceuticals scored higher than 61% of companies evaluated by MarketBeat, and ranked 362nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Amneal Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Amneal Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Amneal Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Amneal Pharmaceuticals are expected to grow by 13.21% in the coming year, from $0.53 to $0.60 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Amneal Pharmaceuticals is -10.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Amneal Pharmaceuticals is -10.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Amneal Pharmaceuticals has a P/B Ratio of 105.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.22% of the float of Amneal Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Amneal Pharmaceuticals has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Amneal Pharmaceuticals has recently increased by 38.44%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Amneal Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Amneal Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.22% of the float of Amneal Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Amneal Pharmaceuticals has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Amneal Pharmaceuticals has recently increased by 38.44%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Amneal Pharmaceuticals has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Amneal Pharmaceuticals this week, compared to 5 articles on an average week.
  • MarketBeat Follows

    1 people have added Amneal Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Amneal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,113,200.00 in company stock.

  • Percentage Held by Insiders

    17.45% of the stock of Amneal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 31.82% of the stock of Amneal Pharmaceuticals is held by institutions.

  • Read more about Amneal Pharmaceuticals' insider trading history.
Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMRX Stock News Headlines

FBI Warns: Wave Of Retiree Cyber Hacks Coming In 2025
Try to think back to the fall of 2008… The pandemic accelerated America's descent into a “no-cash society” by several years…
Amneal Pharmaceuticals announces expanded coverage for Crexont
Amneal Pharmaceuticals announces U.S. launch of Boruzu
See More Headlines

AMRX Stock Analysis - Frequently Asked Questions

Amneal Pharmaceuticals' stock was trading at $7.92 at the start of the year. Since then, AMRX shares have decreased by 6.6% and is now trading at $7.3950.
View the best growth stocks for 2025 here
.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) released its quarterly earnings results on Friday, February, 28th. The company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by $0.03. The company earned $730.52 million during the quarter, compared to analysts' expectations of $708.21 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative trailing twelve-month return on equity of 346.26%.
Read the conference call transcript
.

Amneal Pharmaceuticals' top institutional shareholders include Hennessy Advisors Inc. (0.48%), Assenagon Asset Management S.A. (0.26%), Rhumbline Advisers (0.08%) and Ritholtz Wealth Management (0.04%). Insiders that own company stock include Tushar Bhikhubhai Patel, Tpg Gp A, Llc, Gautam Patel, Andrew S Boyer and Jason B Daly.
View institutional ownership trends
.

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amneal Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), TotalEnergies (TTE), Voyager Therapeutics (VYGR), Broadcom (AVGO) and Waste Connections (WCN).

Company Calendar

Last Earnings
2/28/2025
Today
4/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AMRX
Previous Symbol
NASDAQ:AMRX
Employees
7,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.80
High Stock Price Target
$12.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+47.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
13.78
P/E Growth
N/A
Net Income
$-83,990,000.00
Pretax Margin
-4.59%

Debt

Sales & Book Value

Annual Sales
$2.79 billion
Cash Flow
$1.26 per share
Price / Cash Flow
5.80
Book Value
$0.07 per share
Price / Book
104.36

Miscellaneous

Free Float
255,745,000
Market Cap
$2.26 billion
Optionable
Optionable
Beta
1.06
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:AMRX) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners